COSCIENS Biopharma Inc T.AEZ

RE:Re: Strategic acquisitions

[prophetoffactz]

"PGX scale up is a prime example of where this company is position to fail. 7 months plus behind schedule and no word. Then we need government approval that does not happen over night."

The Edmonton facility was installed and commissioned by the end of Q1 as expected. Then they went to the 'fine tuning' phase and have had multiple production runs which were "almost completed" as of the April 29, 2024 news release. The product could be available by year end with Health Canada approval. The Edmonton facility already has Health Canada approval for natural products so it could be a streamlined process. Also, as noted in the Feb. news release, the oat beta glucan chewy product also received Health Canada approval and is expected to be launched in the second half of this year. Health Canada is very familiar with the company and major global brands also rely on the company's facilities.

Ceapro Inc. Announces Receipt of Site License from Health Canada

 

May 15, 2019

Ceapro at the forefront of pioneering approaches with natural products

EDMONTON, Alberta, May 15, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that both of its two Alberta-based bioprocessing plants, located in Leduc and Edmonton, have received a Site License from the Health Canada Natural and Non-Prescription Health Products Directorate. This license enables the Company to fabricate, package, label, release and distribute final products.

“We are very pleased with the issuance of this license recognizing that our state-of-the-art bioprocessing sites are in compliance with GMP requirements of the Natural Health Products Regulations. Receiving this is a further testament of the Quality Management System being implemented at Ceapro, which has also been recognized by major customers during their audits conducted at the end of 2018. Importantly, the issuance of this license is another important milestone in the transition of Ceapro’s business model from a contract manufacturer to a biopharmaceutical company. This license will enable us to not only produce and sell active ingredients as raw material, but will also allow Ceapro to manufacture and release its own finished products, such as beta glucan tablets and other PGX-processed new chemical entities,” commented Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): [phone]
E: [e-mail]

Issuer:

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555